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Abstract 
The Hedgehog (Hh) family of intercellular signalling proteins have come to be recognised as key mediators 
in many fundamental processes in embryonic development. Their activities are central to the growth, 
patterning and morphogenesis of many different regions within the bodies of vertebrates. In some contexts, 
Hh signals act as morphogens in the dose-dependent induction of distinct cell fates within a target field, in 
others as mitogens in the regulation of cell proliferation or as inducing factors controlling the form of a 
developing organ. These diverse functions of Hh proteins raise many intriguing questions about their mode of 
action. Various studies have now demonstrated the function of Hh signalling in the control of cell 
proliferation, especially for stem cells and stem-like progenitors. Abnormal activation of the Hh pathway has 
been demonstrated in a variety of human tumours. Hh pathway activity in these tumours is required for 
cancer cell proliferation and tumour growth. Recent studies have uncovered the role for Hh signalling in 
advanced prostate cancer and demonstrated that autocrine signalling by tumour cells is required for 
proliferation, viability and invasive behaviour. Thus, Hh signalling represents a novel pathway in prostate 
cancer that offers opportunities for prognostic biomarker development, drug targeting and therapeutic 
response monitoring. 
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Hh signalling pathway 
A much simplified description of the Hedgehog (Hh) pathway includes the Hh ligands, their 
receptor and a few of the molecules that transduce the signal (Fig. 1). In mammals there are three 
distinct Hh ligands [1] with different expression patterns: Sonic Hedgehog (Shh), Indian 
Hedgehog (Ihh) and Desert Hedgehog (Dhh). All three Hh ligands bind the transmembrane 
receptor Patched1 (Ptch1). In the absence of Hh ligand, Ptch1 inhibits a second transmembrane 
protein Smoothened (Smo). Hh binding to Ptch1 relieves the repression of Smo and allows Smo to 
further transduce the Hh signal. This Hh signalling results in the activation of the Gli family of 
transcription factors: Gli1, Gli2 and Gli3. Gli1 and Ptch1, as well as the gene encoding the 
Hedgehog interacting protein (Hip), are Hh response genes, and their expression has been used as 
evidence for active Hh signalling. Expression of Ptch1 or Hip starts a negative feedback loop that 
shuts down Hh signalling by sequestering Hh ligand. In the cytoplasm the Suppressor of Fused 
[Su(Fu)] protein also inhibits transduction of the Hh signal.  
 
 
 
Fig. 1 A simplified model of Hh signalling. The Shh receptor, Patched (Ptch), is a 12-
transmembrane protein with homology to the resistance, nodulation, division (RND) 
bacterial transporter family. Costal2 (Cos), Kinase Fused (Fu), Suppressor of Fused 
(SuFu) (microtubule associated complex). The active Shh signalling peptide is formed 
by an autoprocessing reaction that converts a 45-kDa protein into a 19-kDa signalling 
peptide that is doubly lipid modified, with palmitate and cholesterol moieties at its N 
and C termini, respectively 
 
  
Although the precise cellular roles of Hh signals are still under scrutiny, it is clear that they can 
elicit different responses depending on the context in which the signals operate. Thus, Hh signals 
have been shown to regulate cell fate specification, cell proliferation and cell survival in different 
target cells. Signalling can be short- and long-range, direct and indirect (through the activation of a 
signalling relay), and importantly, concentration-dependent, evoking distinct molecular responses 
at discrete concentration thresholds (a classic morphogen activity).  
 
The identification of many of the signalling factors that mediate cellular communication has 
led to two general conclusions. First, although there are many important signals, most of these fall 
into a few large families of secreted peptide factors: the Wingless-type (Wnt) [2], fibroblast 
growth factor [3], transforming growth factor (TGF)- β superfamily [4], platelet-derived growth 
factor [5] and Hh families.  
Shh and prostate development 
The prostate gland is composed of a secretory epithelial parenchyma and a stroma consisting of 
smooth muscle cells and fibroblasts [6, 7]. The stromal cells elaborate components of the 
extracellular matrix and paracrine factors that regulate epithelial cell proliferation and 
differentiation [8]. The role of mesenchyme in directing growth and morphogenesis during 
embryonic prostate development is well established [9] (Fig. 2).  
 
 
 
Fig. 2. The prostate originates from solid epithelial outgrowths that emerge from the endodermal urogenital sinus below the 
developing bladder. The prostatic buds grow into the adjacent mesenchyme, lengthen to form ducts, arborise and canalise. 
Considerable cellular heterogeneity exists across the prostatic ductal epithelium. Signals derived from the developing 
prostatic stroma are believed to control the rate and fate of proliferating prostate epithelial cells 
The epithelial buds grow and form the prostate ducts. The prostate ducts will elongate and 
branch extensively both prenatally and postnatally until the final elaborate branching structure of 
the mature prostate is achieved. Hh function in the prostate seems to centre around the 
establishment of ductal branching. Shh expression begins in the epithelial layers of the rodent 
urogenital sinus and concentrates at areas of epithelial bud- ding [10]. Levels of Shh transcripts 
continue to be elevated as epithelial invaginations become ductal buds. During duct elongation 
Shh transcripts localise at the growing distal tips [10–12].  
  
The role of Shh in regulating induction, proliferation and differentiation of the developing 
mammalian prostate has been studied most extensively in mouse and rat models.  
 
During prenatal mouse prostate development, Shh activates Gli gene expression in the adjacent 
mesenchyme, and promotes epithelial proliferation and ductal growth [13–16]. Later in prostate 
development, Shh appears to inhibit growth and induce differentiation of epithelial cells into 
postmitotic, terminally differentiated luminal cells [17] (Fig. 3A). The dichotomous actions of Shh 
at different stages of prostate development may be due to differing concentrations of active Shh 
peptide or coregulators such as activin A and TGFb1 or a change in the state of stromal cell 
differentiation [17].  
 
 
 
Fig. 3 A1 The initial formation of prostate buds does not require Shh signalling. 2 At 
prenatal prostate development, Shh promotes epithelial proliferation and ductal growth 
through Gli1 gen expression in the adjacent mesenchyme. 3 Later in prostate 
development, Shh appears to inhibit growth and induce differentiation of transit 
amplifying (TA) epithelial cells into postmitotic terminally differentiated (TD) luminal 
cells. B Epithelial-mesenchymal interactions driven by Shh. During normal prostate 
development Shh signalling is a paracrine event between the epithelium and the 
adjacent stroma 
 
  
The development of the prostate requires Hh signalling, although the initial formation of 
prostate buds does not require Shh. Shh is critical for maintaining appropriate prostate growth, 
proliferation and tissue polarity [18]. In the adult prostate, however, the activity of the Hh pathway 
is quite low [19]. Shh expression appears at approximately the same time as a surge in testosterone 
levels, suggesting that the two may be coordinated. Shh expression in the budding epithelium of 
the urogenital sinus correlates with a functional Hh pathway, as it results in upregulation of the Hh 
pathway proteins Ptch1, Gli1, Hip and bone morphogenetic protein (BMP)4 in the adjacent 
mesenchyme [10–12] (Fig. 3B).  
 
Epithelial Shh expression is concentrated at sites of ductal bud formation and the tips of the 
growing ducts in which it activates Gli-1 and Gli-2 expression in the adjacent mesenchyme. 
Negation of Shh signalling impairs the activation of Gli-1 and Gli-2 expression and inhibits ductal 
outgrowth [13–15]. Because this effect entails primarily an inhibition of epithelial cell 
proliferation, it suggests that epithelial Shh expression activates stromal-mediated paracrine 
signals that feed back and stimulate epithelial cell proliferation [14] (Fig. 3B). Epithelial–
mesenchymal interactions driven by Hh ligand are a central theme in the morphogenesis of 
prostate growth (Table 1).  
Table 1. Role of Shh between epithelial–mesenchymal interactions [25] 
 
Expression of Shh and Gli in the adult human prostate 
No significant differences in levels of Shh expression or Gli-1 expression in the normal (N) and benign prostatic 
hyperplasia specimens. 
Active Shh signalling between epithelium and stroma 
This association is equivalent and suggests that epithelial Shh activity determines the stromal expression of Gli-1. 
Shh expression drives stromal Gli-1 expression 
Shh secreted by the epithelium signals to stromal cells and activates stromal cell Ptch-1 and Gli-1 expression in a 
paracrine loop. 
 
 
The role of the other mammalian Hh proteins is less clear: Dhh expression is not detected 
during the time of prostate development [13, 20], and low levels of Ihh were consistently 
observed. 
Shh signalling in prostate cancer 
As an important regulator of tissue polarity, active Hh signalling is required for ductal 
morphogenesis and proliferation during prostate development [21]. The adult prostate, on the other 
hand, does not contain active Hh signalling.  
 
Recent studies showed a key role of Shh signalling in mediating endoderm-derived tissue 
formation, including prostate formation. Shh was expressed during prostatic branching 
morphogenesis, suggesting involvement in the initiation of androgen-dependent prostate 
development [22, 23], but analyses in mutant phenotypes revealed that Shh expression did not 
appear to be regulated by androgens. Androgen supplement was shown to reverse Shh mutant 
phenotypes [24], indicating that the role of Shh could be replaced by androgens during prostate 
development.  
  
In concordance with observations in other tumours, several lines of evidences have indicated 
Hh signalling in prostate tumorigenesis. A series of articles defined the role of Hh signalling in the 
growth and metastasis of advanced prostate cancer [25–28]. Molecular mechanisms and pathway 
components discovered in biochemical, genetic and molecular studies of Hh signalling during 
development, particularly in stem cell biology, are now demonstrated to be behind characteristics 
of tumour cells such as proliferation and invasive behaviour.  
In vitro models  
Prostate cancer cell lines, including PC3, LNCaP, DU145, 22RV1 and TSU, were shown to 
express high levels of Hh or its target genes [25–28]. Hh signalling modulated metastatic potential 
of rodent prostate cancer cell lines. Also when PrE cells, a putative prostate epithelium pro- 
genitor cell line, were stably transfected for Gli expression, the cells exhibited unlimited growth in 
vitro and formed aggressive subcutaneous tumours after transplantation into an athymic mouse 
[26].  
In vivo models  
A xenograft model was used to elucidate paracrine interactions between Shh-expressing human 
LNCaP tumour cells and host mouse stromal cells [25]. The LNCaP cells were genetically 
engineered to express Shh at high levels that dramatically accelerate tumour growth with increased 
Gli expression.  
 
There are reported data showing Hh-induced in vivo prostate tumorigenesis in a mouse model 
induced by Hh overexpression that is initiated from normal status: Hh overexpression caused 
prostatic intraepithelial neoplasia (PIN) formation and the concomitant acceleration of prostate 
carcinoma metastatic activity. Overexpressions of Hh patterns were comparable to human 
conditions and gross morphological effects were similar [29].  
 
These results indicated that the characteristics of PIN and prostate cancer formation were 
specifically due to Hh overexpression.  
Human profiles  
There are reports that activation of the Hh pathway occurs frequently in advanced human 
prostate cancer. High levels of Hh target genes, Ptch1 and Hip, are detected in over 70% of 
prostate tumours with Gleason scores 8–10, but in only 22% of tumours with Gleason scores 3–6 
[28]. 
 
Other researchers [30] observed abundant Gli-1 expression in 80% of prostate cancer tissues 
examined and speculated that Hh signalling could play an important role in prostate cancer. Shh 
pathway components, for example Gli, were detected in adult human prostate cancer, often with 
enhanced levels in tumours as compared to those in the normal status.  
 
Activation of Hh signalling causes elevated expression of target genes Ptch1 and Hip. Thus, 
increased protein expression of Ptch1 and Hip indicates activation of the Hh expression, and thus 
the Su(Fu) inactivation appears to contribute to activation of Hh signalling in prostate tumours. As 
a negative regulator of the Hh pathway, Su(Fu) inhibits the function of Gli molecules, leading to 
inactivation of this pathway [31–33]. Su(Fu) is also reported to affect beta-catenin function [34].  
  
Shh and genetic relations 
Genetic mapping studies for familial prostate cancer have identified numerous chromosomal 
regions linked to prostate cancer susceptibility. On chromosome one a genetic association has been 
demonstrated between clinically significant prostate cancer and the brain tumour glioblastoma 
multiforme at 1p36 (Carcinoma Prostate Brain, CAPB), suggesting the presence of a common 
oncogene for these tumours [35–37].  
 
It is interesting to note that multiple components of the Hh pathway are present within 
chromosomal regions associated with susceptibility to human prostate cancer (Fig. 4).  
 
 
 
Fig. 4 Prostate cancer genetic associations and the Hh pathway. Adapted from Datta and Datta [59] 
Analysis of data from genetic studies of familial prostate cancer showed that regions 
implicated in prostate cancer susceptibility contained the genes coding for Hh pathway 
components, including Gli1, Gli3, Smo and Su(Fu) [38–42].  
 
In addition the Su(Fu) gene is localised at 10q24, a region with a frequent loss of heterozygosis 
(LOH) in prostate cancer [43, 44].  
 
Taken together, these findings suggest that activation of the Hh pathway involves prostate 
cancer progression. There might be several mechanisms by which the Hh pathway is activated in 
advanced prostate cancers, including loss of Su(Fu) protein expression, overexpression of Shh or 
other alterations (Table 2).               
  
Table 2 Mechanisms by which the Hh pathway is activated: overexpression of Shh or Su(Fu) inactivation [28] 
 
Elevated expression of Hh target genes in prostate cancer specimens 
The Hh pathway appears to be frequently activated in advanced or metastatic prostate cancers. 
In prostate cancers with Gleason score 3–6, 4 out of 18 specimens were positive for Ptch1 (22%), whereas 16 out of 22 
undifferentiated carcinomas (Gleason Scores of 8–10) expressed Ptch1 and Hip (73%). 
Altered expression of Su(Fu) and Shh in prostate cancer specimens 
Loss of Su(Fu) protein may be associated with prostate cancer progression. 
Some prostate tumours had no detectable Su(Fu) protein expression. 
The normal tissues retained expression of Su(Fu), indicating that alteration of Su(Fu) is a somatic event. 
Prostate cancers with low Gleason scores, however, frequently have detectable Su(Fu) protein. 
Of the 16 Ptch1 positive prostate cancer specimens with Gleason scores 8–10, 9 have no detectable Su(Fu) protein. 
In total, 11 of 27 Ptch1 positive prostate cancer specimens have no detectable Su(Fu) protein. 
 
 
Epithelial–mesenchymal interactions 
A growing body of evidence indicates that the stroma may undergo phenotypic and/or 
genotypic changes that enhance prostate cancer growth. Despite previous reports regarding 
involvement of Hh protein in the cancer formation within sites of epithelial–mesenchymal inter- 
actions, it has been reported that Hh can actually induce prostate cancer [45]. On the stromal side, 
evidence has been accumulated to indicate a “reactive stroma” that provides secretory factors that 
contribute to tumour growth and progression [46]. It has been shown that dedifferentiation of 
stromal smooth muscle [47] and distortion of epithelial cell lineage proportions [48] are factors in 
prostate carcinogenesis. Indeed, there are factors that are involved in both epithelial and stromal 
cells, with activities shifted between both sides or be- tween different forms of a same factor, in 
correlation with progression from normal to malignant stages [49–52]. In this study, it has been 
demonstrated that Hh overexpression caused prostate tumorigenesis from normal status to prostate 
cancer formation, and such transformation involved morphological characteristics within both the 
epithelial and the stromal sides. It has also been shown that Hh protein was detected within both 
the epithelial and the stromal cells during tumorigenesis, with concomitant loss of fibromuscular 
layer.  
 
Experiments performed with the LNCaP xenograft tumour model demonstrated that Shh 
overexpression in LNCaP cells leads to increased tumour stromal Gli-1 expression and that Shh 
overexpression dramatically accelerates tumour growth. These data suggest that Hh signalling 
from prostate cancer cells to the stroma can elicit the expression of paracrine signalling, which 
pro- motes tumour growth [53]. However, a survey of adult human prostate tissues reveals 
substantial levels of Shh signalling in normal, hyperplasic and malignant prostate tissue. In cancer 
specimens, the Shh expression is localised to the tumour epithelium, whereas Gli-1 expression is 
localised to the tumour stroma. A tight correlation between the levels of Shh and Gli-1 expression 
suggests active signalling between the tissue layers.  
 
Previous reports have shown that prostate cancer-associated stromal cells are phenotypically 
different from the stromal cells of the normal prostate, and the fact that reactive stroma can induce 
myofibroblast phenotype in prostate cancer [8, 54].  
 
Studies of tumour-associated stromal cells have shown enhanced capacity to promote tumour 
growth in vivo [55, 56]. More recently tumour-associated stromal cells and normal prostate 
stromal cells have been shown to exhibit different responses to paracrine stimulation with pigment 
epithelium-derived factor [57]. The mechanism for stromal activation has not been defined and the 
mechanisms by which stromal cells influence tumour growth are also not well understood. 
However, the distinctive character of the stromal compartment associated with prostate cancer may 
set the stage for a categorically different response to Shh signalling. Whereas Shh signalling in the 
stromal context of the normal prostate may help regulate the balance between proliferation and 
terminal differentiation, a similar level of signalling in the context of a cancer-associated reactive 
stroma may induce paracrine signals that promote tumour cell proliferation (Fig. 5).  
 
 
 
Fig. 5 Autocrine and paracrine signalling changes in Hh: during normal prostate 
development Shh signalling is a paracrine event between the epithelium and the 
adjacent stroma, while in prostate cancer tumours, Shh signalling appears to occur as an 
autocrine loop within cancerous epithelially derived cells. Adapted from Datta and 
Datta [59] 
Tumours may be able to recruit normal stromal cells to support tumour growth by inducing 
expression of a variety of angiogenic and growth factors in a paracrine fashion [58]. The stromal 
reaction in cancer resembles the activity of stromal cells in wound healing and may create 
conditions that favour tumour progression.  
Conclusions 
The Hh signalling cascade is pivotal to embryonic development, and is involved in patterning a 
diverse range of vertebrate structures.  
 
During foetal prostate development, Shh expression by the urogenital sinus epithelium 
activates Gli-1 expression in the adjacent mesenchyme and promotes out- growth of the nascent 
ducts. Shh signalling is downregulated at the conclusion of prostate ductal development.  
 
Studies of prostate development suggest that Hh signalling is critical for normal ductal 
morphogenesis [15, 27, 28]. Epithelial Shh expression is concentrated at sites of ductal bud 
formation and the tips of the growing ducts in which it activates Gli-1 and Gli2 expression in the 
adjacent mesenchyme. Negation of Shh signalling impairs the activation of Gli-1 and Gli2 
expression and inhibits ductal outgrowth. Because this effect entails primarily an inhibition of 
epithelial cell proliferation, it suggests that epithelial Shh expression activates stromal-mediated 
paracrine signals that feed back and stimulate epithelial cell proliferation [15].  
 
Hh is a regulatory protein during embryonic development and its abnormal activation in adult 
tissues has been implicated in tumorigenesis within sites where epithelial–mesenchymal 
interactions take place. In the prostate, Hh signalling activation was observed during advanced 
cancer progression and metastasis, but whether Hh overexpression can initiate prostate 
tumorigenesis remains unknown.  
 
Hh pathway genes in human prostate tissue reveal significant maintenance levels of Shh and 
Gli gene expression in the normal adult human prostate and comparably high levels of Hh 
signalling in prostate cancer and benign prostatic hyperplasia.  
 
In cancer specimens, the Shh expression is localised to the tumour epithelium, whereas Gli-1 
expression is localised to the tumour stroma. Tight correlation between the levels of Shh and Gli-1 
expression suggests active signalling between the tissue layers. These data suggest that Hh 
signalling from prostate cancer cells to the stroma can elicit the expression of paracrine signals, 
which promote tumour growth.  
 
Thus, while currently only speculative, the possibility exists that mutations or changes at 
multiple levels of the Hh pathway may lead to an increased risk of prostate cancer. This is coupled 
with data that indicate that the Hh pathway is present and expressed in human prostate tumours. 
Analysis of Shh protein immunoreactivity in both normal prostate tissues and tumours shows that 
it was demonstrated and upregulated with the more aggressive tumours, with the Shh-positive 
tumours having a higher Gleason grade.  
 
The identification of signalling pathways that regulate the growth of advanced prostate cancer, 
in particular of androgen-independent tumour cells, is of utmost importance. These signalling 
pathways may represent both biomarkers for the development of advanced androgen refractory 
prostate cancer and targets for drug design that could be used, alone or together with hormonal 
treatments, to stop the growth of advanced prostate cancer.  
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